Design, preparation and application of novel IL-2, INF alpha and Fc fusion protein
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of IL-2 and fusion protein, applied in the field of biomedicine, can solve problems such as weak specificity, large side effects, and short half-life
Pending Publication Date: 2022-08-05
NANJING JSIAMA BIOPHARMACEUTICALS LTD
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] In order to solve the above problems, the present invention discloses the design, preparation and application of a novel fusion protein of IL-2, INFα and Fc. Through gene mutation, the binding ability of IL-2 and its receptor, INFα and its receptor can be changed to solve the current problem. It has the disadvantages of weak drug specificity, short half-life and large side effects
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0059] ELISA detection and receptor IL-2Rα protein binding ability
[0060]The packages are different (10000ng / ml, 2500ng / ml, 625ng / ml, 156.25ng / ml, 39.0625ng / ml, 9.765625ng / ml, 2.44140625ng / ml, 0). Laoshenzhou), 100UL / holes at 4 ° C; closed with 3 % skim milk powder at 37 ° C for 1h; add 1ug / ml fusion protein per hole and 100ul each of its control samples, and incubate 1h at 37 ° C; then add HRP -labeled sheep anti -human IL IL IL people IL. -2PAB, incubation at 37 ° C for 1h, after 10 minutes of color rendering, read OD450 on the enzyme label. Consequences figure 2 Essence
Embodiment 2
[0062] ELISA detection and receptor IL-2Rβ protein binding ability
[0063] The packages are different (10000ng / ml, 2500ng / ml, 625ng / ml, 156.25ng / ml, 39.0625ng / ml, 9.765625ng / ml, 2.44140625ng / ml, 0). Laoshenzhou), 100UL / holes at 4 ° C; closed with 3 % skim milk powder at 37 ° C for 1h; add 1ug / ml fusion protein per hole and 100ul each of its control samples, and incubate 1h at 37 ° C; then add HRP -labeled sheep anti -human IL IL IL people IL. -2PAB, incubation at 37 ° C for 1h, after 10 minutes of color rendering, read OD450 on the enzyme label. Consequences image 3 Essence
Embodiment 3
[0065] ELISA detection and receptor IFNαr2 protein binding ability
[0066] The packages are different concentrations (10000ng / ml, 2500ng / ml, 625ng / ml, 156.25ng / ml, 39.0625ng / ml, 9.765625ng / ml, 2.44140625ng / ml, 0) protein (10359-H02H, Yiliang Shenzhou ), 100UL / hole at 4 ° C overnight; closed 3 % skimmed milk powder at 37 ° C for 1h; add 1ug / ml fusion protein per hole and 100ul each of its control samples, incubate 1h 37 ° C; then add rabbit anti -human interferon 2,37 ℃ Incubation 1h, then add HRP -labeled sheep anti -rabbit H+L, incubate for 1h 37 ° C, and after 10 minutes of color rendering, read OD450 on the enzyme label. Consequences Figure 4 Essence
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
According to the invention, modifications aiming at human interleukin-2 (IL-2) and interferon alpha (IFN alpha) are included; the fusion protein is formed by IL-2, INF alpha or IL-2 / INF alpha double factors and Fc after modification; as well as the design, preparation and use of these fusion proteins; respectively fusing the mutant IL-2 and the mutant INF alpha (double factors) at the N terminal or the C terminal of the Fc; fusing the mutant IL-2 at the N terminal or the C terminal of the Fc; respectively fusing the mutant INF alpha at the N end or the C end of the Fc; l234A / L235A mutation is introduced into the Fc segment at the same time, so that the binding capacity of the Fc segment and a receptor FcgRIII is reduced; m252Y / S254T / T256E mutation is introduced, so that the half-life period of the protein is prolonged; through gene mutation, the binding capacity of IL-2 and a receptor thereof and the binding capacity of INFalpha and a receptor thereof are changed, mutants better than wild type mutants are obtained, the binding capacity with NK cells and CD8 + T cell receptors is improved, and the defects that existing drugs are weak in specificity and large in side effect are overcome.
Description
Technical field [0001] The invention is a biomedical technology field, which involves the design, preparation and use of the new IL-2 and INFα and FC fusion proteins. Background technique [0002] IL-2, also known as T cell growth factor, is the gene is located in No. 4 chromosomes, including a sequence of 7KB, consisting of 133 amino acids, and the molecular weight is about 15kd. IL-2 acts through IL-2R. IL-2R includes three subunit, IL-2Rα (ie CD25), IL-2Rβ (ie CD122), and IL-2R γ (ie CD132). Three sub-submissions can form three forms of receptor: high binding force receptor contains all three sub-meter IL-2Rα / β / β / β, and the binding force receptor contains IL-2Rβ / γ two sub-macro Receptor IL-2Rα. Among them, IL-2Rβ and IL-2R γ are necessary for IL-2 to activate the downstream signal pathway. When IL-2 is combined with IL-2Rβ and IL-2Rγ at the same time, the two receptor subunit forms a heterogeneous diode, phosphorylationization The STAT5 in the cells enters the corresponding ge...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more